지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2004.12
- 수록면
- 381 - 389 (9page)
이용수
초록· 키워드
오류제보하기
The toxicity of CKD-602 was investigated at doses of 3, 9, and 27 mg/kg in rats, when the same total dose of CKD-602 was administered over 24 hr-continuous infusion or bolus injection. At 3 and 9 mg/kg, the 24-hr infusion group showed a more decreased WBC count on day 3, compared with the bolus group. Administration of CKD-602 caused more toxic effects such as the significant decreases of RBC counts, hematocrit, hemoglobin, and platelet count on day 7 postadministarion in the 24-hr infusion group than in the bolus group. Administration of CKD-602 also caused histopathological changes such as extramedullary hemopoiesis of liver and spleen, hyperplasia of femoral bone marrow, and caecal dilation. These toxic effects were more severe in the 24-hr infusion group than in the bolus injection group, indicating that the toxicity of CKD-602 may be dependant upon the duration of administration.
목차
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULT
DISCUSSION
ACKNOWLEDGEMENTS
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Comparison of Single-Dose Toxicity by Intravenous Infusion or Bolus Injection with CKD-602, a Camptothecin Anticancer Agent in Rats (I): Toxic Effects with regard to Mortality and Clinical Signs
Toxicological Research
2004 .12
-
신규 캄토테신계 항암제 CKD-602의 약물동태: 흡수
약학회지
1998 .01
-
신규 캄토테신계 항암제 CKD-602의 약물동태: 분포, 대사 및 배설
약학회지
1998 .01
-
Toxicity Study of CKD-602, a Camptothecin Anticancer Agent: 5-Day Repeated Intravenous Administration in Rats
The journal of applied pharmacology : the official journal of the Korean Society of Applied Pharmacology
2004 .01
-
Acute Toxicity of CKD-602, a New Anticancer Agent, in Rats
The journal of applied pharmacology : the official journal of the Korean Society of Applied Pharmacology
2004 .01
-
Absorption, Distribution, Metabolism, and Excretion of CKD-732, a Novel Antiangiogenic Fumagillin Derivative, in Rats, Mice, and Dogs
Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea
2004 .01
-
구강암 세포주에 대한 CKD-602의 항암 효과
대한구강악안면외과학회지
2005 .01
-
Development of CKD-602, a novel camptothecin derivative, for anticancer agent
대한약학회 학술대회
2000 .01
-
Camptothecin계 항암제 CKD-602의 유전독성평가 ( Genotoxicity Studies of An Anticancer Agent of Camptothecin Series, CKD-602 )
한국환경성돌연변이·발암원학회지
1998 .09
-
5-Day Repeated Intravenous Dose Toxicity Study of a New Camptothecin Anticancer Agent CKD-602 in Rats
Toxicological Research
2004 .03
-
In Vitro Pharmacodynamics of CKD-602 in HT-29 Cells
Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea
2002 .01
-
변형 근치적 유방절제술 시행 환자의 방사선 치료 시 3D-bolus와 step-bolus의 비교 평가
대한방사선치료학회지
2016 .01
-
Association of Demographic and Socioeconomic Factors With Risk Factors for Chronic Kidney Disease
예방의학회지
2015 .01
-
Higher Risk for All-cause Mortality of Staphylococcus aureus Bacteremia in Patients with Non-Dialysis Dependent Chronic Kidney Disease
Infection and Chemotherapy
2020 .01
-
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
Cancer Research and Treatment
2016 .01
-
3D 프린터를 이용한 Customized Bolus 제작에 관한 연구
대한방사선치료학회지
2015 .01
-
CKD-712, (S)-1-(α-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, Inhibits the NF-κB Activation and Augments Akt Activation during TLR4 Signaling
Immune Network
2011 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2009-513-015230752